Catalysts · VRTX · CIK 875320 · page 2 of 2

VRTX catalysts and FDA events, page 2.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on VRTX PDUFA dates and upcoming catalysts. This page continues the list.

Past catalysts and FDA decisions (continued)

DateDrugCompanyEventIndicationStatusSource
December 20, 2024vanzacaftorVRTXFDA approvalpeople with CF 6 years of age and olderApprovedSEC Form 8-K
December 13, 2024Orkambi (ivacaftor; lumacaftor)VRTXLabel expansion—ApprovedopenFDA Drugs@FDA
October 31, 2023exagamglogene autotemcel (CTX001)VRTXAdvisory committee—CompletedFDA advisory committee calendar
May 3, 2023Kalydeco (ivacaftor)VRTXLabel expansion—ApprovedopenFDA Drugs@FDA
April 26, 2023Trikafta (Copackaged) (elexacaftor, ivacaftor, tezacaftor; ivacaftor)VRTXFDA approval—ApprovedopenFDA Drugs@FDA
September 2, 2022Orkambi (ivacaftor; lumacaftor)VRTXLabel expansion—ApprovedopenFDA Drugs@FDA
June 8, 2021Trikafta (Copackaged) (elexacaftor, ivacaftor, tezacaftor; ivacaftor)VRTXLabel expansion—ApprovedopenFDA Drugs@FDA
December 21, 2020Kalydeco (ivacaftor)VRTXLabel expansion—ApprovedopenFDA Drugs@FDA
December 21, 2020Symdeko (Copackaged) (ivacaftor; ivacaftor, tezacaftor)VRTXLabel expansion—ApprovedopenFDA Drugs@FDA
December 21, 2020Trikafta (Copackaged) (elexacaftor, ivacaftor, tezacaftor; ivacaftor)VRTXLabel expansion—ApprovedopenFDA Drugs@FDA
September 24, 2020Kalydeco (ivacaftor)VRTXLabel expansion—ApprovedopenFDA Drugs@FDA
October 21, 2019Trikafta (Copackaged) (elexacaftor, ivacaftor, tezacaftor; ivacaftor)VRTXFDA approval—ApprovedopenFDA Drugs@FDA
August 7, 2018Orkambi (ivacaftor; lumacaftor)VRTXFDA approval—ApprovedopenFDA Drugs@FDA
February 12, 2018Symdeko (Copackaged) (ivacaftor; ivacaftor, tezacaftor)VRTXFDA approval—ApprovedopenFDA Drugs@FDA
Every catalyst is quoted from VRTX’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.